ArticleEye (London, England)2014
Glaucoma prescribing trends in England 2000 to 2012.
Article in Eye (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Topical Beta-Blockers and Cardiovascular Mortality: Systematic Review and Meta-Analysis with Data from the EPIC-Norfolk Cohort Study.Ophthalmic epidemiology · 2016Pooled it
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.Ophthalmology · 2016Pooled it
- Regional variation and trends in prostaglandin analogue prescribing for glaucoma in England 2019-2024.Eye (London, England) · 2026Article
- Trends in First-Line Glaucoma Treatment from 2013 to 2024: A Multi-institutional and Multinational Cohort Study.Ophthalmology and therapy · 2026Article
- Branded Compared with Generic Latanoprost in Glaucoma Therapy: Where Do We Stand?Advances in therapy · 2026Review
- Sustaining Ophthalmic Practices for the Future: A High-Value Care Approach to Environmental Responsibility.Ophthalmology and therapy · 2025Review
- Users of reimbursed glaucoma medications in Finland in 1986-2023: A nationwide study.Acta ophthalmologica · 2025Article
- Glaucoma treatment and deprivation: time-series analysis of general practice prescribing in England.BJGP open · 2024Article
- Estimation of Topical Glaucoma Medication Over-Prescription and Its Associated Factors.Journal of clinical medicine · 2023Article
- Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?The British journal of ophthalmology · 2022Review
- Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan.Journal of personalized medicine · 2022Article
- The Use of Generic Medications for Glaucoma.Journal of ophthalmology · 2020Review
- Article
- Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma.Ophthalmology and therapy · 2018Review
- Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis.British journal of cancer · 2018Article
- OpenPrescribing: normalised data and software tool to research trends in English NHS primary care prescribing 1998-2016.BMJ open · 2018Article
- Review
- [Possibilities and limitations of eye drops for glaucoma therapy].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Review
- Geographical variation in glaucoma prescribing trends in England 2008-2012: an observational ecological study.BMJ open · 2016Observational
- The Prevalence and Incidence of Glaucoma in Denmark in a Fifteen Year Period: A Nationwide Study.PloS one · 2015Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn 2009, the National Institute for Clinical Excellence (NICE) published guidance on the treatment of ocular hypertension and glaucoma. The aim of the present study was to describe the impact this guidance had on glaucoma prescribing and to describe recent prescribing trends in England.
methodPrescribing cost analysis data held by NHS Business Authority for the years 2000-2012 was analysed.
resultsThe number of prescriptions dispensed increased by 67% from 4.76 million in 2000 to 7.96 million in 2012. Over the same time period, drug costs increased by 88% from £55.2 million to £103.7 million. Prescriptions for prostaglandin analogues increased fourfold, while there was a threefold decrease in the use of beta-blockers. The most commonly prescribed glaucoma medication was latanoprost. The introduction of generic latanoprost in 2012 more than halved the cost associated with this medication. NICE guidance appeared to have had no effect on the total number of prescriptions or the classes of medications prescribed.
conclusionThe introduction of the NICE guidelines did not change glaucoma prescribing practice, although it is not clear whether this represents non-adherence to the guidelines or whether the guidelines embodied pre-existing practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.